We previously showed [34] after a 29-year follow up of the GOH cohort, that individuals in the upper quartile of the fasting insulin had an increased risk, although with borderline statistical significance, for all-site cancer mortality (HR = 1.37, 95% CI: 0.94, 2.00, p = 0.097). Here, INS is linked to cancer.